abstract: Fetuses with Turner's syndrome or trisomies 21, 18 and 13 show excess of skin, which can be visualized by ultrasonography as increased nuchal translucency at 11-13 +6 weeks' gestation. The objective of this study was to gain insight in the development and distribution of blood vessels, lymphatic capillaries of the cutis and lymphatic collectors of the cutis and subcutis and to study developmental changes with increasing gestation. Immunofluorescence of cryosections with 10 specific antibodies was used to investigate the nuchal skin of three fetuses with Turner syndrome's and to differentiate lymphatics, lymph capillaries (FLT4, PTN 63, LYVE1, PROX1), blood vessels (KDR, CD 31, PDPN), blood clotting activity (von Willebrand factor), basement membranes and big vessels (Laminin, Collagen Type IV). The findings were compared with those in seven fetuses with trisomy 21 and two fetuses each with trisomies 18 or 13, respectively, as well as six normal controls. Immunoreactive receptors for vascular endothelial growth factors (FLT4) were decreased in lymphatic capillaries of the skin of Turner fetuses. Accordingly, LYVE1 was scarce and PROX1 staining was less intense in the dermis of Turner fetuses. Lymphatic collectors were, however, evenly stained. In normal fetuses and in those with trisomies, lymphatic capillaries were evenly distributed. We conclude that lymphatic capillary hypoplasia might be responsible for nuchal cystic hygroma in Turner syndrome. The biological basis for increased nuchal translucency in trisomies may however be different.
Introduction
Turner syndrome is associated with subcutaneous accumulation of fluid in the neck region that can be visualized sonographically at 11 -13 +6 weeks' gestation as massively increased nuchal translucency thickness (Nicolaides et al., 1994; Snijders et al., 1996) . Possible mechanisms for increased translucency include dilatation of the jugular lymph sacs based on a developmental delay in the formation of a connection with the venous system, or a primary abnormal growth or proliferation of the lymphatic channels interfering with the normal flow of lymphatic fluid into the venous systems (van der Putte, 1977) . In normal embryos, nuchal lymphatics mainly develop from the jugular segments of the cardinal veins (Wigle and Oliver, 1999) . The early lymphatics transiently decrease their connections with the veins to form the juguloaxillary lymph sacs. Subsequently, they may reconnect to the jugular veins and drain lymphatic fluid (Van der Putte and Van Limborøgh, 1980) . Because the mammalian lymphatic system originates from the embryonic veins, its morphogenesis involves the acquisition of lymphatic endothelial cell identity and separation from the blood vessel network (Adams and Alitalo, 2007; Karpanen and Alitalo, 2008) . The development of the lymphatic vessels involves multiple steps the molecular components of which have just begun to emerge (Hong et al., 2004; Adams and Alitalo, 2007; Karpanen and Alitalo, 2008) . These include fate determination by the consecutive action of the SRY (sex-determining region Y) box 18 and Prospero-related homeobox 1 (PROX1) transcription factors, SOX18 and PROX1, to trigger lymphatic endothelial cell differentiation from the cardinal vein (Wigle and Oliver, 1999; Wigle et al., 2002; François et al., 2008) , as well as lateral migration in response to the vascular endothelial growth factor VEGF-C that promotes sprouting of PROX1 positive lymphatic endothelial cells via the VEGFR3 receptor (Karkkainen et al., 2004) . Maturation of the lymphatic primordium in later stages involves the transcription factors FOXC2 and NFATc1, the arterial regulator ephrin B2, and smooth muscle cell contacts Mäkinen et al., 2005; Adams and Alitalo, 2007; Norrmén et al., 2009) . Required for the separation of the two major vascular networks in mammals is also a hematopoietic signaling pathway via the tyrosine kinase SYC and the SRC homology 2 (SH2) domaincontaining leukocyte-specific phosphoprotein of 76 kDa, SLP76 (Abtahian et al., 2003) . Mouse embryos lacking the SYK kinase and the SLP76 adaptor protein develop abnormal blood-lymphatic endothelial connections . SYK and SLP76 are signaling mediators activated downstream of the 'immunoreceptor tyrosine-based activation motif' (ITAM)-containing immunoreceptors and integrins, and the essential domains of SLP76 for ITAM signals are those which most efficiently support separation between lymphatic and blood vessels , suggesting that Syk and Slp76 may be required for integrin-mediated guidance of the circulating endothelial precursor cells into the vascular endothelium (Karpanen and Alitalo, 2008) .
There have been previous indications that an abnormal increase in nuchal translucency may be related to an abnormal development of lymph and venous vessels of the fetal neck. A microscopical study, using hematoxylin and eosin, Masson's trichrome stain and factor VIII-related antigen staining (Mukai et al., 1980) , examining the lymphatic vessels in the skin of spontaneously aborted fetuses with cervical cystic hygromas, reported that there were numerous dilated lymphatic vessels, whereas in Turner syndrome there were very few such vessels. In the skin of normal fetuses, lymphatic vessels were evenly distributed (Chitayat et al., 1989) . A more recent study investigating jugular lymphatic sac volume using ultrasound found that the nuchal translucency enlargement precedes the enlargement of jugular lymphatic sacs (Bekker et al., 2006a) . Also, the antibody against the lymphatic marker PROX1 showed absent or diminished staining in the enlarged jugular lymphatic sacs of fetuses with aneuploidy and nuchal edema, whereas LYVE1 staining was normal (Bekker et al., 2006b (Bekker et al., , 2008 . In addition, the enlarged jugular lymphatic sacs showed some blood vessel characteristics and the lumen contained blood cells and smooth muscle cells that lined the wall, compatible with a loss in lymphatic identity (Bekker et al., 2006b (Bekker et al., , 2008 .
The objective of this study was to gain further insight into the development and distribution of blood vessels and lymphatics in the nuchal skin of aneuploid fetuses beyond studying the enlarged jugular lymphatic sacs between 11 and 20 weeks, by looking individually at lymphatics, both lymphatics and blood vessels, vessels with blood clotting activity and big vessels with basement membranes. In particular, lymphatic capillaries of the cutis and lymphatic collectors at the border between cutis and subcutis were studied in detail, to investigate whether scarcity of lymphatic capillaries may be responsible for the characteristic phenotype of nuchal cystic hygroma.
Materials and Methods

Patient material
Nuchal skin of three fetuses with the Turner's syndrome, seven fetuses with trisomy 21, two fetuses with trisomy 18, two fetuses with trisomy 13 and six normal control fetuses from 11 to 16 weeks of gestation was investigated (Table I ). An additional six normal control fetuses at 11
+4 or 19 +1 weeks of gestation, respectively, were included to study vessel development with increasing gestational age. Gestation was calculated from the first day of the last menstrual period. Chorionic villous sampling was carried out after the request of the parents to determine the karyotype. Written informed consent was obtained, and the study was approved by the hospital ethical committee. Tissue collection was made in accordance with the Polkinghorne guidelines on the research use of fetal tissues (Polkinghorne, 1989) . Skin tissues were dissected after therapeutic termination of pregnancy or from pregnancies that were terminated for psychosocial reasons. Tissues were embedded into Tissue Tek (Leica, Bensheim, Germany), frozen and stored at 2708C until further procedures were carried out. For all fetuses with aneuploidies and for chromosomally normal controls, gestation at diagnosis and at termination as well as the nuchal translucency measurement is given in Table I . Fetuses with the Turner's syndrome were terminated at 11
+0
, 11
+6 and 14 +0 weeks, the respective nuchal translucency measurement was 7.4, 6.2 and 6.0 mm.
Antibodies
Ten antibodies were applied to characterize the distribution of blood vessels and lymphatics in fetal cryosections. Their characteristics are summarized in Table II (Kato et al., 2006; Baluk and McDonald, 2008) . To differentiate blood vessels and lymphatics, antibodies were used to selectively stain lymph vessels (FLT4, PTN63, LYVE1 and PROX1; have used antibodies against the Vascular Endothelial Growth Factor Receptor FLT4 (VEGFR3), because its expression becomes mainly restricted to lymphatic endothelium during development, except for the high endothelial venules in lymphatic organs (Kaipainen et al., 1995) . In addition, we used antibodies against PTN63 (5 ′ -nucleotidase) because it is specifically expressed in lymphatic endothelial cells, and LYVE1, an endothelial transmembrane receptor that can bind Hyaluronan. The biological function is not yet identified, as the knockout does not have a developmental phenotype (Gale et al., 2007) . It serves as an early and specific marker for lymphatic endothelial cells in lymphatic capillaries but is absent in blood vessels (Banerji et al., 1999; Mäkinen et al., 2005) . Furthermore, we used antibodies against PROX1, a nuclear transcription factor expressed in a subpopulation of endothelial cells (Wilting et al., 2002) that by budding and sprouting give rise to the lymphatic system (Wigle and Oliver 1999; Wigle et al., 2002) . Some slides were additionally stained with antiserum against podoplanin (PDPN), a transmembrane glycoprotein that promotes lymphatic endothelial cell adhesion, migration and tubulogenesis (Schacht et al., 2003) .
To further distinguish between blood vessels and lymphatics, antibodies against KDR or CD31 were used to stain both blood vessels and lymphatics (Table II) . KDR (VEGFR2) is 81% identical with FLT4 in the tyrosine kinase domain (Pajusola et al., 1992) and is known to stain both types of vessels in the activated tissue (Partanen et al., 1999) and embryos (Wilting et al., 1997) . CD31 is an endothelial cell adhesion molecule present on both blood vessels and lymphatics.
An antibody detecting von Willebrand factor (vWF) ( Table II) served as a marker for blood clotting activity and was used to stain both blood vessels and lymphatics and to further characterize lymphatics.
Finally, basement membranes were stained using antibodies against laminin and collagen Type IV (Table II) , to distinguish lymphatic capillary vessels from big vessels including lymphatic collecting vessels .
Immunohistochemistry
Cryosections of nuchal skin from fetuses with Turner's syndrome, trisomies 21, 18 and 13 and from chromosomally normal controls, to specifically stain 'lymphatics', were stained with antibodies against FLT4 (rabbit anti-human, Santa Cruz Biotechnology, Santa Cruz, CA, USA, polyconal, 1:100), PTN63 (kindly supplied by H.-G. Mannherz from the Department of Anatomy and Embryology, Bochum, Germany, mouse antihuman, monoclonal, 1:4) as described earlier (Bekker et al., 2008) , LYVE1 (rabbit anti-human; Reliatech, Braunschweig, Germany, polyclonal, 1:200) and PROX1 (rabbit anti-human; Reliatech, Braunschweig, Germany, polyclonal, 1:1000). Some slides were additionally stained with antiserum against PDPN (mouse anti-human; Reliatech, Wolfenbüttel, Germany, monoclonal, 1:100). Cryosections to stain 'both blood vessels and lymphatics' were stained using antibodies against KDR (kindly supplied by Dr H.A. Weich from the Helmholtz Centre for Infection Research, Braunschweig, Germany, polyclonal, 1:50) and CD31 (mouse anti-human; RDI, Biozol, Eching, Germany, monoclonal, 1:50). To measure 'blood clotting' activity, antibodies were used against the vWF (rabbit anti-human, Dako, Hamburg, Germany, polyclonal, 1:100). To stain 'basement membranes' antibodies against collagen Type IV (Heyl, Berlin, Germany; monoclonal, 1:100) and laminin (rabbit anti-human, Sigma, Munich, Germany, polyclonal, 1:100) were used.
Frozen sections (20 mm) were collected on chrome-alum-gelatinecoated slides. After being dried, they were blocked with 1% bovine serum albumin in 0.1 M potassium phosphate buffer (pH 7.6) for 10 min and incubated with primary monoclonal or polyclonal antibodies against the different extracellular matrix components (60 min at room temperature). After being rinsed with phosphate buffer, the sections were incubated with affinity-purified goat-anti-mouse IgG for the monoclonal antibodies and with goat-anti-rabbit IgG for the polyclonal antibodies, both conjugated with Cy3 from Dianova (Hamburg, Germany, 1:200). Controls were carried out in two ways. Cryostat sections from aneuploid and euploid fetuses were processed in the same way as described above, except for the omission of the primary antibody to assess the degree of non-specific staining. Alternatively, pre-immune mice serum was used instead of the first monoclonal antibody and pre-immune rabbit serum instead of the first polyclonal antibody for specificity controls. The sections were examined by epi-fluorescence microscopy (Zeiss, Axio Imager Z1 
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The type of vessel and character of each antibody is summarized.
Results
Immunostaining of lymphatics
In fetuses with the Turner syndrome, the chain of dilated vessels at the dermis-subcutis junction was stained by the FLT4 antibody indicating their lymphatic origin. In the dermis, there was scarcity of stained vessels indicating lymphatic hypoplasia in the dermis (Figs 1f and 2b  d) . The FLT4 antibody stained both large and small diameter vessels throughout the dermis and subcutis in the nuchal skin of trisomic fetuses, with fewer vessels in trisomy 13 ( Fig. 3a-c , middle panel). There were no obvious changes from large to smaller diameter vessels in chromosomally normal controls (Fig. 3d , middle panel, Table III ). In nuchal skin from fetuses with the Turner syndrome, there was a chain of large diameter vessels that stained positive for PTN63 at the border between dermis and subcutis. The upper dermis was devoid of stained vessels (Fig. 1e , Table III ). These results were in line with early PTN63 antibody studies (von Kaisenberg et al., 1999a) and with basement membrane antibody studies using laminin and collagen type IV (von Kaisenberg et al., 1998a, b) .
Antibodies against the lymphatic marker PROX1 detected small diameter vessels throughout the dermis and subcutis in the nuchal skin of chromosomally normal fetuses from 11 to 16 weeks (Fig. 4b) . In contrast, specific staining by PROX1 antibody was missing in the nuchal skin of Turner fetuses (Fig. 4a) . A similar result was obtained using LYVE1 antibody that stained small vessels and possibly groups of cells in the nuchal dermis and subcutis of chromosomally normal fetuses (Fig. 4d) , but did not stain vessels in the nuchal skin from Turner fetuses (Fig. 4c) . +0 weeks using antibodies against collagen type IV (a), laminin (b), KDR (c), vWF (d), PTN63 (5 ′ -nucleotidase) (e) and FLT4 (f), Bar: 50 mm. Note the intense staining of small-to medium-sized vessels in the upper dermis using both the collagen type IV and laminin antibodies (a and b). A chain of dilated vessels at the dermis -subcutis junction is stained by the KDR antibody. Smaller vessels in the upper dermis and in the subcutis are also stained (c). The chain of dilated vessels at the dermis-subcutis junction is stained using the vWF and there are medium-sized vessels in the upper part of the dermis (d). Using the PTN63 antibody, there is a chain of large diameter vessels at the border between dermis and subcutis. The upper dermis is devoid of stained vessels (e). A similar finding is obtained using the FLT4 antibody with a chain of dilated vessels at the dermis -subcutis junction and scarcity of stained vessels in the upper dermis indicating lymphatic hypoplasia (f). The specific antibodies are studied individually and compared with controls (ep, epidermis; de, dermis; sc, subcutis). The chain of dilated vessels at the dermis -subcutis junction in Turner fetuses is also stained by the FLT4 antibody. In the dermis, there is scarcity of stained vessels indicating lymphatic hypoplasia in the dermis (b). Medium-sized to big lymphatic and blood vessels are stained in the Turner syndrome fetus at 14 +0 weeks using KDR (c). Again, there is less staining of medium-sized and small vessels using the FLT4 antibody, indicating hypoplasia of lymphatics (d). Hence, the immunohistochemical findings and size of nuchal translucency in both Turner syndrome fetuses are similar.
Co-staining of blood vessels and lymphatics
In the nuchal skin of Turner fetuses, the KDR antibody stained a chain of dilated vessels at the dermis-subcutis junction. Smaller vessels in the upper dermis and in the subcutis were also stained (Figs 1c and  2a ). In fetuses with trisomies 21, 18 and 13, vessels were stained throughout the skin without prominent differences (Fig. 3a -c , upper panel). There were also no major differences in vessel staining in two Turner syndrome fetuses at 11 and 14 weeks gestation, with similar nuchal translucency ( Fig. 2a and c) . Vessel distribution was typical for Turner syndrome as has been described earlier (Figs 1c and 2a; von Kaisenberg et al., 1999a) . In the nuchal skin of chromosomally normal fetuses, the KDR antibody detected both large and small vessels throughout the dermis and subcutis (Fig. 3d, upper panel) . Keratinocytes of the developing epidermis in normal and chromosomally abnormal fetuses were also stained, predominantly in superficial layers (Fig. 3d, upper panel) . The CD31 antibody detecting both types of vessels, clearly stained vessels in the dermis and subcutis of both euploid fetuses and fetuses with the Turner syndrome in a similar pattern (Fig. 4e and f, Table III) . We then wished to confirm our previous findings further by double immunofluorescent staining for a blood vascular marker together with a lymphatic vascular marker. Therefore, we selected slides from one control, one Turner syndrome and one trisomy 21 fetus, respectively, and performed immunostaining of CD31, as a blood vascular marker, together with PDPN as pan-lymphatic vascular marker. This analysis identified PDPN in the basal cells of the epidermis and in lymphatic vessels (Fig. 5, green) , whereas CD31 was mainly detected in blood vessels (Fig. 5, red) . In agreement with our results described above, the Turner fetal tissue exhibited some CD31 staining but PDPN staining for lymphatic vessels was absent.
Blood clotting activity in vessels
Antibodies against the vWF stained the chain of dilated vessels at the dermis-subcutis junction in fetuses with Turner's syndrome, and visualized medium-sized vessels in the upper part of the dermis (Fig. 1d) . In trisomic fetuses, staining was detected in the epidermis, and vessels In the nuchal skin of trisomic fetuses, the KDR antibody detects both large and small vessels throughout the dermis and subcutis. Keratinocytes of the developing epidermis are also stained, predominantly in superficial layers. In trisomic fetuses, FLT4 staining visualizes vessels in the dermis and subcutis, with fewer vessels in trisomy 13. Immunoreactivity towards the vWF protein is present in the epidermis, and vessels are also found in the dermis and subcutis, with no major difference to the normal control.
were found in the dermis and subcutis (Fig. 3a-c, bottom panel) . Control experiments after pretreatment with acetone showed no difference in background staining. The vWF antibody stained large and small diameter vessels throughout the dermis and subcutis in the nuchal skin of chromosomally normal fetuses from 11 to 16 weeks (Fig. 3d, bottom panel) .
Basement membranes and big vessels
The laminin antibody stained all basement membranes in euploids, fetuses with trisomies and Turner's syndrome (Fig. 1b) , most prominently the epidermal basement membrane and the basement membranes of all great vessels, blood capillaries and skin appendages. Antibodies against FLT4, PTN63, LYVE1, PROX1 and PDPN are lymphatic endothelial markers; KDR and CD31 were used to stain both blood vessels and lymphatics; vWf was used to stain both blood vessels and lymphatics with blood clotting activity, and laminin and collagen type IV stain basement membranes of vessels. The epidermis was not part of this investigation, but the epidermal basement membrane was strongly stained using laminin and collagen type IV. The upper region of the subcutis did not contain many vessels and was therefore also disregarded in this table. Each slide was examined by two independent investigators, and the intensity of immunofluorescent staining was broadly classified using four categories: 2, absent; +/2, poor staining; +, moderate staining; ++, strong staining; nk, unknown.
Figure 4
Turner syndrome (left) and control (right), antibodies against PROX1 (a and b), against LYVE1 (c and d) and against CD31 (e and f). PROX1 antibody detect small diameter vessels throughout the dermis and subcutis in the nuchal skin of chromosomally normal fetuses from 11 to 16 weeks. In comparison, specific staining by PROX11 antibody is missing in the nuchal skin of Turner fetuses. LYVE1 antibody also staines small lymphatic capillary vessels and possibly groups of cells in the nuchal dermis and subcutis of chromosomally normal fetuses, but does not stain the nuchal skin from Turner fetuses. CD31 antibody clearly staines vessels in the dermis and subcutis of both euploid fetuses and fetuses with Turner syndrome of the same gestational age in a similar pattern.
Lymphatic hypoplasia and nuchal translucency
Laminin was also detectable in the dermal fibroblasts of trisomy 18 fetuses (not shown). In Turner's syndrome, intense staining of smallto medium-sized vessels in the upper dermis was noted (Table III) .
Immunostaining with the collagen type IV antibody visualized all basement membranes in chromosomally normals, fetuses with trisomies and Turner's syndrome, in particular, the epidermal basement membrane and the basement membranes of collecting vessels, blood capillaries and skin appendages. The dermal connective tissue was essentially devoid of staining, except for an occasional labeling of dermal fibroblasts that was most prominent in trisomy 13 (not shown). In Turner's syndrome, there was intense staining of small-to medium-sized vessels in the upper dermis (Table III, Fig. 1a ).
Vascular development with increasing gestation
Vessel development with increasing gestation from 11 to 19 weeks was investigated using antibodies against KDR (Fig. 6, upper panel) , FLT4 (Fig. 6, middle panel), vWF (Fig. 6, lower panel) , collagen type IV (Fig. 7, upper panel) , Laminin (Fig. 7 , middle panel) and PTN63 (Fig. 7 , lower panel) on normal fetal tissue sections. No significant changes with gestation were observed for any of the antibodies used, further supporting the view that our findings observed in the pathological situation cannot be attributed to changes with gestational age.
Discussion
The objective of this study was to gain further insight into the development and distribution of blood vessels and lymphatics in the nuchal skin of fetuses with Turner syndrome or trisomies 21, 18 and 13 as well as chromosomally normal controls, all between 11 and 20 weeks, and to study potential developmental changes with increasing gestational age.
The main findings of this study in Turner's syndrome are a chain of dilated vessels at the dermis-subcutis junction detected using the FLT4 antibody and a scarcity of stained vessels in the dermis indicating lymphatic hypoplasia. This contrasts with chromosomally normal fetal tissue where large and small diameter vessels were more evenly distributed in the dermis and subcutis. In trisomies, vessels were also stained in the dermis and subcutis, albeit with fewer vessels in trisomy 13. The differential expression of VEGFR3 (FLT4) may have important consequences for VEGF signaling. VEGF plays important roles in angiogenesis and vascular development during embryogenesis by autocrine and paracrine signaling (Aitkenhead et al., 1989; Shifren et al., 1994; Adams and Alitalo, 2007; Karpanen and Alitalo, 2008) . There are three known VEGF receptors VEGFR1, VEGFR2 and VEGFR3, all of which possess specific tyrosine kinase activities (Joukov et al., 1996) . However, the expression of VEGFR3 is tightly regulated (Joukov et al., 1996; Partanen et al., 1999) . We have used monoclonal antibodies against FLT4 (VEGFR3), a tyrosine kinase domain in this receptor, because it becomes mainly restricted to lymphatic endothelia during development except for some high endothelial venules (Joukov et al., 1996) . It has been shown previously that FLT4 is a marker of lymphatic vessels except for some high endothelial postcapillary venules, which are located in lymph nodes in human adult tissues and may also play a role during development (Joukov et al., 1996) . In murine development, the FLT4 antibody first detects the VEGFR3 tyrosine kinase receptor in angioblasts of head mesenchyme, the cardinal vein and the allantois (8.5 day p.c.; Kaipainen et al., 1995) . At 12.5 day p.c. developing venous and presumptive lymphatic endothelia can be detected, with arterial endothelia being negative (Kaipainen et al., 1995) . FLT4 later becomes restricted to vascular plexuses devoid of stained cells representing developing lymphatic vessels (Kaipainen et al., 1995) . In adults, only lymphatic endothelia and some high endothelial venules express FLT4 mRNA (Kaipainen et al., 1995) .
The importance of the vascular endothelial growth factor receptor-3 gene (VEGFR3, FLT4) for lymphatic vessel development has also been strongly indicated by its identification as the gene responsible for hereditary lymphoedema type I (Nonne -Milroy disease), an autosomal dominant condition characterized by deficient lymphatic drainage due to hypoplastic/aplastic lymphatic vessels. A child of an affected father presented with increased nuchal translucency at 13 weeks. Although the skin edema had resolved at 20 weeks, lymphedema of the lower limbs developed after birth (Souka together with podoplanin as pan-lymphatic vascular marker. Podoplanin immunoreactivity is detected in the basal cells of the epidermis and in lymphatic vessels (green), whereas CD31 is mainly detected in blood vessels (red). Turner fetal tissue exhibits some CD31 staining but lacks podoplanin staining for lymphatic vessels. Upper panel 10× magnification, lower panel 20× magnification. et al., 2002 ). An inactivating mutation in this gene alters the proteinreceptor and causes deficient VEGFR3 signaling (Irrthum et al., 2000; Karkkainen et al., 2000) . Further cases with severe VEGFR3 mutations have since been reported in patients with Milroy disease (Connell et al., 2009) , and a recessive mode of inheritance has been attributed to hypomorphic VEGFR3 mutations (Ghalamkarpour et al., 2009a) . Most recently, VEGFR3 mutations as well as FOXC2 mutations have been reported in a subset of sporadic patients diagnosed with fetal edema (Ghalamkarpour et al., 2009b) . A further antibody directed against LYVE1, a hyaluronan-binding protein that is degrading hyaluronan in lymphatics and is absent in blood vessels (Banerji et al., 1999) , showed little staining in the dermis of Turner fetuses. This is noteworthy in regard to a previous study, investigating hyaluronan in the skin of fetuses with aneuploidies that did not find an increased amount of hyaluronan in Turner fetuses (Bö hlandt et al., 2000) . It appears that most degradation of hyaluronan does not occur within the skin itself; hyaluronan is rather transported through the lymphatic system to distant lymph nodes where .90% of the glycosaminoglycan in the afferent lymph is degraded or re-enters the circulation to be rapidly endocytosed by liver endothelial hyaluronan receptors (Fraser et al., 1988; Fraser and Laurent, 1989) . If LYVE1 were scarce, hyaluronan degradation could be decreased and hyaluronan would be expected to accumulate. Hyaluronan was, however, increased (Bö hlandt et al., 2000) and LYVE1 staining was normal in trisomy 21 in the present study, suggesting that hyaluronan regulation might not be simply a result of LYVE1-mediated degradation.
The homeobox gene PROX1 encodes a specific marker of a subpopulation of endothelial cells that by budding and sprouting give rise to the murine lymphatic system (Zinovieva et al., 1996; Wigle and Oliver, 1999) . When the development of the lymphatic vasculature was arrested in Prox1 knockout mice at E14.5, most of the heterozygous and all of the homozygous Prox1 embryos developed severe skin edema similar to the one observed in Turner fetuses (Wigle and Oliver, 1999) . In our study, antibodies against the lymphatic marker PROX1 detected small diameter vessels throughout the dermis and subcutis in the nuchal skin of euploid fetuses from 11 to 16 weeks. In comparison, specific staining by PROX1 antibody was missing in the nuchal skin of Turner fetuses. Although various theories have been Lymphatic hypoplasia and nuchal translucency proposed regarding the origin of the lymphatic system, the most widely accepted theory is from Sabin (1909) , suggesting a venous origin of the lymphatics. Venous endothelial cells give rise to lymph sacs by localized sprouting. Such lymphatic sacs may then grow and sprout further to form the lymphatics of all organs (Sabin, 1909) . The development of the lymphatics from mesenchymal cells next to blood vessels was suggested by others (Kampmeier, 1912) . A venous origin of the lymph sacs, but mesenchymal origin of the other lymphatics has also been proposed (Huntington, 1908) . Grafting experiments in quail and chick have shown, however, that the lymph sacs are not the exclusive source of the lymphatics (Wilting et al., 2000; Papoutsi et al., 2001) . Studies in chick embryos and human fetuses using PROX1 have shown that PROX1 is expressed in restricted ectodermal, mesodermal and endodermal compartments as well as in some scattered mesodermal cells of early embryos, supporting the previous observations of lymphangioblasts in the paraxial and splanchnic mesoderm (Rodriguez-Niedenfuhr et al., 2001) . The additional staining of lymphatics using FLT4, PROX1 and LYVE1 in the present study confirm and extend our previous report of lymphatic vessel hypoplasia in the skin of Turner fetuses (von Kaisenberg et al., 1999a) . The finding of lymphatic hypoplasia in the skin of patients with Turner's syndrome would also be consistent with studies investigating women with ovarian dysgenesis due to monosomy X. Lymphangiography showed hypoplasia of superficial lymph vessels of the lower limbs, the pelvis and in the retroperitoneal space (Vittay et al., 1980) . Although hypoplasia of lymphatic vessels could be clearly demonstrated, it remains unclear why lymphatic vessels do not develop sufficiently in Turner's syndrome fetuses. Haploinsufficiency for an X-chromosomally encoded regulatory gene could play a yet unappreciated role for lymphatic hypoplasia.
Several additional experiments were performed that corroborated the above-described findings. In the nuchal skin of Turner fetuses, both the KDR and the CD31 antibody stained a chain of dilated vessels at the dermis-subcutis junction but smaller vessels in the upper dermis and in the subcutis were also stained and both immunoreactivities were evenly distributed in blood vessels and lymphatics of euploids and fetuses with trisomies. These findings helped to distinguish the lymph-specific antibodies from those also staining blood vessels, and the results confirm the lymph-specific character of FLT4, PTN64, LYVE1 and PROX1. In fetuses with Turner syndrome, the chain of dilated vessels at the dermis-subcutis junction was also stained and there were medium-sized vessels in the upper part of the dermis using antibodies against the vWF. The results indicate that blood vessels in the upper dermis of Turner syndrome fetuses were stained as well as in trisomies and controls. Again, this helps to confirm the lymph-specific character of FLT4, PTN63, LYVE1 and PROX1 and the significance of the results obtained with these markers. Both the laminin and the collagen type IV antibody stained all basement membranes. In Turner syndrome, there was intense staining of small-to medium-sized vessels in the upper dermis. In euploids, fetuses with trisomies and Turner syndrome, in particular in the epidermal basement membrane and in the basement membranes of all large vessels, blood capillaries and skin appendages were stained (Table III) . This helped to distinguish small, medium-sized and big vessels. In normal fetal lymph system development, there seems to be a phase during which the lymph sacs are poorly connected to the venous system (Sabin, 1909; Huntington, 1914) . If there were a delay in the connection extending into the late first trimester, the lymph sacs cannot drain effectively and lymphatic fluid accumulates within them. If the connection does not occur at all, the lymphatic sacs may enlarge to form cystic structures, as in cystic hygroma (Castelli et al., 2003; Gittenberger-de Groot et al., 2004; Haak et al., 2002; Bekker et al., 2006a Bekker et al., , b, 2008 . Although previous immunohistochemical studies described abnormalities of the lining of the cavities of jugular lymphatic sacs (Bekker et al., 2008) , our study used specific markers to investigate the distribution of lymph capillaries in first-trimester fetuses with aneuploidies.
We report, that receptors for vascular endothelial growth factors (FLT4) are less abundant in lymphatics of the skin of Turner fetuses indicating shortage of lymph capillaries. In parallel, a hyaluronanbinding protein involved in the degradation of hyaluronan in lymphatics (LYVE1) is absent in blood vessels and scarce in the dermis of Turner fetuses, and a homeobox protein which in, knockout mice, appears responsible for a phenotype similar to Turner syndrome (PROX1) is also less stained in the skin of Turner syndrome fetuses. These findings corroborate very early observations using an antibody against the 5 ′ -nucleotidase of lymph endothelium (PTN63) (von Kaisenberg et al., 1999a) . In chromosomally normal fetuses and those with trisomies, however, there is even distribution of lymphatics stained by these antibodies. A recent study using sonic hedgehog (Shh) expression and the forkhead transcription factor FOXC2 in the skin of first trimester trisomy 21 fetuses indicated the loss of lymphatic identity in trisomy 21 fetuses and a shift towards a blood vessel wall phenotype (de Mooij et al., 2009) . A common pathophysiological pathway for all chromosomal abnormalities explaining the transient nature and the gestation of the onset of increased nuchal translucency at the end of the first trimester has not been identified yet. Narrowing of the aortic isthmus has been proposed as one of the mechanisms, is commonly found in all trisomies and is most marked in Turner's syndrome were the increase of the nuchal translucency is highest (Hyett et al., 1995a (Hyett et al., , b, 1997 . It may be, that a slight increase in the diameter of the aortic isthmus substantially reduces the vascular resistance (equation of Hagen -Poisseuille) thus leading to spontaneous resolution of the edema (von Kaisenberg et al., 1999b) .
Altogether, our results provide strong evidence that in Turner syndrome lymphatic vessel hypoplasia might be responsible for the clinically visible nuchal cystic hygroma. The developmental basis for increased nuchal translucence in trisomic fetuses appears to be different from Turner syndrome (von Kaisenberg et al., 1998a (von Kaisenberg et al., , b, 1999a .
